At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,051 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
In Brief
An observational study for Cancer. Completed, enrolled 3,051 participants across 58 sites.
Detailed Summary
The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartAug 2013
First PostedSep 2013
Primary CompletionJan 2018
Study CompletionOct 2022
TodayJul 2026
First PostedSep 19, 2013
Enrollment StartAug 29, 2013
Primary CompletionJan 1, 2018
Study CompletionOct 13, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.8 years ago